Pexidartinib + Probenecid
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics in Healthy Volunteers
Conditions
Pharmacokinetics in Healthy Volunteers
Trial Timeline
Feb 27, 2017 → Mar 30, 2017
NCT ID
NCT03138759About Pexidartinib + Probenecid
Pexidartinib + Probenecid is a phase 1 stage product being developed by Daiichi Sankyo for Pharmacokinetics in Healthy Volunteers. The current trial status is completed. This product is registered under clinical trial identifier NCT03138759. Target conditions include Pharmacokinetics in Healthy Volunteers.
What happened to similar drugs?
5 of 5 similar drugs in Pharmacokinetics in Healthy Volunteers were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03138759 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics in Healthy Volunteers